Given the association identified between the low copy number of ULBP3 and Fas and a poor survival in GBM patients, their increased expression on T98G cells following Olaparib treatment indicates a potential new mechanism through which PARP inhibition may confer clinical benefits in GBM patients. The gene discussed is ULBP3; the disease is glioblastoma.